Empagliflozin and kidney function decline in patients with type 2 diabetes: A slope analysis from the EMPA-REG OUTCOME trial

Journal of the American Society of Nephrology

Volumn 29, Issue 11, 2018, Pages 2755-2769

  Wanner, Christoph ^a   Heerspink, Hiddo J L ^b   Zinman, Bernard ^c   Inzucchi, Silvio E ^d   Koitka Weber, Audrey ^a,e,f   Mattheus, Michaela ^e   Hantel, Stefan ^e   Woerle, Hans Juergen ^g   Broedl, Uli C ^e   Von Eynatten, Maximilian ^e   Groop, Per Henrik ^f,h,i  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MOUNT SINAI HOSPITAL   (Canada)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF ULM   (Germany)

^h FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; PLACEBO; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MACROALBUMINURIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADMINISTRATION AND DOSAGE; AGED; CLINICAL TRIAL; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL;

AGED; BENZHYDRYL COMPOUNDS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85055838159     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2018010103     Document Type: Article

References (24)

1. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, et al.: Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15: 613-621, 2013
2. Levine MJ: Empagliflozin for type 2 diabetes mellitus: An overview of phase 3 clinical trials. Curr Diabetes Rev 13: 405-423, 2017
3. Anderson JE, Wright EE Jr., Shaefer CF Jr.: Empagliflozin: Role in treatment options for patients with type 2 diabetes mellitus. Diabetes Ther 8: 33-53, 2017
4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.: EMPAREGOUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEngl J Med 373: 2117-2128, 2015
5. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al.: EMPA-REG OUTCOME Investigators: Empagliflozin and progression of kidney disease in type 2 diabetes. NEngl JMed 375: 323-334, 2016
6. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetesmellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134: 752-772, 2016
7. Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al.: Glomerularhyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28: 1023-1039, 2017
8. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al.: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587-597, 2014
9. Skrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, et al.: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57: 2599-2602, 2014
10. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al.: EMPA-REG RENAL trial investigators: Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 369-384, 2014
11. Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, et al.: The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59: 1860-1870, 2016
12. Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al.: EMPA-REG OUTCOME Investigators: Empagliflozin and clinical outcomes in patients with type 2 diabetesmellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137: 119-129, 2018
13. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al.: Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPAREG OUTCOME™). Cardiovasc Diabetol 13: 102, 2014
14. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, et al.: Effects of empagliflozin on the urinary albumin-tocreatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5: 610-621, 2017
15. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al.: GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64: 821-835, 2014
16. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V: Canagliflozin slows progression of renal function decline independently of glycemic effects. J AmSoc Nephrol 28: 368-375, 2017
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
18. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, et al.: Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). AmJ Kidney Dis 63: 244-250, 2014
19. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, et al.: Chronic Kidney Disease Prognosis Consortium: Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: A meta-analysis. BMJ 346: f324, 2013
20. Greene T: A model for a proportional treatment effect on disease progression. Biometrics 57: 354-360, 2001
21. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, et al.: CREDENCE study investigators: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46: 462-472, 2017
22. Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, et al.: DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab 20: 1102-1110, 2018
23. Anonymous: Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 7: 2097-2109, 1996
24. Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, et al.: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80: 282-287, 2011